CD274 and type 1 diabetes mellitus: Anti-PD-1 agents (nivolumab, pembrolizumab, cemiplimab, sintilimab, and camrelizumab), anti-PD-L1 agents (atezolizumab, avelumab, and durvalumab), and an anti-CTLA-4 monoclonal antibody (ipilimumab) have been reported to cause type 1 diabetes.